Does the expression of HPV16/18 E6/E7 in head and neck squamous cell carcinomas relate to their clinicopathological characteristics?

International Journal of Oncology

Volumn 35, Issue 5, 2009, Pages 983-988

  Yamakawa Kakuta, Yoshiko ^a   Kawamata, Hitoshi ^a   Doi, Yutaka ^a   Fujimori, Takahiro ^a   Imai, Yutaka ^a  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Head and neck squamous cell carcinoma; Human papilloma virus; p53

Indexed keywords

HUMAN PAPILLOMAVIRUS TYPE 16 E6 PROTEIN; HUMAN PAPILLOMAVIRUS TYPE 18 E7 PROTEIN; PROTEIN P53; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ADULT; AGED; ARTICLE; CANCER STAGING; CARCINOMA; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; HEAD AND NECK CARCINOMA; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; KOILOCYTOSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; SQUAMOUS CELL CARCINOMA; TUMOR CLASSIFICATION; TUMOR LOCALIZATION; VERRUCOUS CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; DNA-BINDING PROTEINS; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM STAGING; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS INFECTIONS; PROGNOSIS; REPRESSOR PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 70449553852     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000412     Document Type: Article

References (30)

1. Parkin DM, Bray F, Ferlay J and Pisani P: Estimating the world cancer burden. Int J Cancer 94: 153-156, 2001.
2. Kawamata H, Nakashiro K, Uchida D, Harada K, Yoshida H and Sato M: Possible contribution of active MMP2 to lymphnode metastasis and secreted cathepsin L to bone invasion of newly established human oral-squamous-cancer cell lines. Int J Cancer 70: 120-127, 1997. (Pubitemid 27059715)
3. Kawamata H, Uchida D, Hamano H, Kimura-Yanagawa T, Nakashiro K, Hino S, Omotehara F, Yoshida H and Sato M: Active-MMP2 in cancer cell nests of oral cancer patients: Correlation with lymph node metastasis. Int J Oncol 13: 699-704, 1998. (Pubitemid 28435345)
4. Kawamata H, Uchida D, Nakashiro K, Hino S, Omotehara F, Yoshida H and Sato M: Haematogenous cytokeratin 20 mRNA as a predictive marker for recurrence in oral cancer patients. Br J Cancer 80: 448-452, 1999. (Pubitemid 29213199)
5. Uchida D, Kawamata H, Nakashiro K, Omotehara F, Hino S, Hoque MO, Begum NM, Yoshida H, Sato M and Fujimori T: Low-dose retinoic acid enhances in vitro invasiveness of human oral squamous-cell-carcinoma cell lines. Br J Cancer 85: 122-128, 2001. (Pubitemid 32695727)
6. Uchida D, Kawamata H, Omotehara F, Nakashiro K, Kimura-Yanagawa T, Hino S, Begum NM, Hoque MO, Yoshida H, Sato M and Fujimori T: Role of HGF/c-met system in invasion and metastasis of oral squamous cell carcinoma cells in vitro and its clinical significance. Int J Cancer 93: 489-496, 2001. (Pubitemid 32701407)
7. Hoque MO, Kawamata H, Nakashiro K, Omotehara F, Hino S, Uchida D, Harada K, Begum NM, Yoshida H, Sato M and Fujimori T: Dysfunction of the p53 tumor suppressor pathway in head and neck cancer. Int J Oncol 21: 119-126, 2002.
8. Uchiga D, Begum NM, Almofti A, Nakashiro K, Kawamata H, Tateishi Y, Hamakawa H, Yoshida H and Sato M: Possible role of stromal-cell-derived factor-1/CXCR4 signaling on lymph node metastasis of oral squamous cell carcinoma. Exp Cell Res 290: 289-302, 2003. (Pubitemid 37272173)
9. Kawamata H, Omotehara F, Nakashiro K, Uchida D, Shinagawa Y, Tachibana M, Imai Y and Fujimori T: Oncogenic mutation of the p53 gene derived from head and neck cancer prevents cells from undergoing apoptosis after DNA damage. Int J Oncol 30: 1089-1097, 2007.
10. Herrero R, Castellsague X, Pawlita M, Lissowska J, Kee F, Balaram P, Rajkumar T, Sridhar H, Rose B, Pintos J, Fernandez L, Idris A, Sanchez MJ, Nieto A, Talamini R, Tavani A, Bosch FX, Reidel U, Suijders PJF, Meijer CJLM, Viscidi R, Munoz N and Franceschi S: Human papillomavirus and oral cancer: The International Agency for Research on Cancer multicenter study. J Natl Cancer Inst 95: 1772-1783, 2003. (Pubitemid 38008900)
11. Huang B, Chen H and Fan M: A postulated role for human papillomavirus (HPV) in the transformation and proliferation of oral squamous cell carcinoma (OSCC). Med Hypotheses 1-3, 2007.
12. Dell G and Gaston K: Human papillomaviruses and their role in cervical cancer. Cell Mol Life Sci 58: 1923-1942, 2001.
13. Zur Hausen H: Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2: 342-350, 2002. (Pubitemid 37328947)
14. Clifford GM, Smith JS, Plummer M, Munoz N and Franceschi S: Human papillomavirus types in invasive cancer worldwide: a meta-analysis. Br J Cancer 88: 63-73, 2003. (Pubitemid 36241220)
15. Bosch FX and de Sanjose S: The epidemiology of human papillomavirus infection and cervical cancer. Dis Markers 23: 213-227, 2007. (Pubitemid 47015785)
16. Munger K, Baldwin A, Edwards KM, Hayakawa H, Nguyen CL, Owens M, Grace M and Huh KW: Mechanisms of human papillomavirus-induced oncogenesis. J Virol 78: 11451-11460, 2004.
17. Narisawa-Saito M and Kiyono T: Basic mechanisms of high-risk human papillomavirus-induced carcinogenesis: Roles of E6 and E7 proteins. Cancer Sci 98: 1505-1511, 2007. (Pubitemid 47308443)
18. Strati K and Lambert PF: Role of Rb-dependent and Rbindependent functions of papillomavirus E7 oncogene in head and neck cancer. Cancer Res 67: 11585-11593, 2007.
19. Badaracco G, Venuti A and Morello R: Human papillomavirus in head and neck carcinomas: prevalence, physical status and relationship with clinical/pathological parameters. Anticancer Res 20: 1301-1306, 2000. (Pubitemid 30240718)
20. Van Houten VM, Snijders PJ and van den Brekel MW: Biological evidence that human papillomaviruses are etiologically involved in a subgroup of head and neck squamous cell carcinomas. Int J Cancer 93: 232-235, 2001.
21. Wiest T, Schwarz E, Enders C, Flechtenmacher C and Bosch FX: Involvement of intact HPV16 E6/E7 gene expression in head and neck cancers with unaltered p53 status and perturbed pRb cell cycle control. Oncogene 21: 1510-1517, 2002. (Pubitemid 34226138)
22. Balz V, Scheckenbach K, Gotte K, Bockmuhl U, Petersen I and Bier H: Is the p53 inactivation frequency in squamous cell carcinomas of the head and neck underestimated? Analysis of p53 exons 2-11 and human papillomavirus 16/18 E6 transcripts in 123 unselected tumor specimens. Cancer Res 63: 1188-1191, 2003. (Pubitemid 36348693)
23. Cheng YW, Wu MF, John Wang J, Yeh KT, Goan YG, Chiou HL, Chen CY and Lee H: Human papillomavirus 16/18 E6 oncoprotein is expressed in lung cancer and related with p53 inactivation. Cancer Res 67: 10686-10693, 2007.
24. Baker CC, Phelps WC, Lindgren V, Braun MJ, Gonda MA and Howley PM: Structural and transcriptional analysis of human papillomavirus type 16 sequences in cervical carcinoma cell lines. J Virol 61: 962-971, 1987. (Pubitemid 17044004)
25. Schwarz E, Freese UK, Gissmann L, Mayer W, Roggenbuck B and Stremlau A: Structure and transcription of human papillomavirus sequences in cervical carcinoma cells. Nature 314: 111-114, 1985. (Pubitemid 15142033)
26. Tachibana M, Kawamata H, Fujimori T, Omotehara F, Horiuchi H, Ohkura Y, Igarashi S, Kotake K and Kubota K: Dysfunction of p53 pathway in human colorectal cancer: Analysis of p53 gene mutation and the expression of the p53-associated factors p14ARF, p33ING1, p21WAF1 and MDM2. Int J Oncol 25: 913-920, 2004.
27. Oyasu R, Nan L, Szumel RC, Kawamata H and Hirohashi S: p53 gene mutations in human urothelial carcinomas: analysis by immunohistochemistry and single-strand conformation polymorphism. Mod Pathol 8: 170-176, 1995.
28. Villa LL, Costa RLR, Petta CA, Andrade RP, Paavonen J, Iversen OE, Olsson SE, Hoye J, Steinwall M, Johannessen GR, Ellstrom AA, Elfgren K, von Krogh G, Lehtinen M, Malm C, Tamms GM, Giacoletti K, Lupinacci L, Railkar R, Taddeo FJ, Bryan J, Esser MT, Sings HL, Saah AJ and Barr E: High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 95: 1459-1466, 2006. (Pubitemid 44863348)
29. Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, Jenkins D, Schuind A, Clemens SAC and Dubin G: Sustained efficacy up to 4·5 years of a bivalent L1 virus-like particle vaccine against human papillo\mavirus types 16 and 18: follow-up from a randomized control trial. Lancet 367: 1247-1255, 2006.
30. Rambout L, Hopkins L, Hutton B and Fergusson D: Prophylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trials. CMAJ 177: 469-479, 2007. (Pubitemid 47359770)